



**MYELOPROLIFERATIVE DISEASES**

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Fedratinib (Inrebic)	0
1.2 Momelotinib (Omjjara)	2
1.3 Ruxolitinib (Jakavi)	10
1.4 Hydroxycarbamide	127

Q2 How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

**This is the number of patients who were admitted with a diagnosis of one of these ICD10 codes rather than treated.**

Diagnosis with ICD10 codes	Number patients treated
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3	20
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3	5
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3	19
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1	14

Q3. How many patients with **Myelofibrosis** (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
3.1 Fedratinib (Inrebic)	0
3.2 Momelotinib (Omjjara)	2
3.3 Ruxolitinib (Jakavi)	1

3.4 Hydroxycarbamide	0
3.5 Peginterferon Alfa-2a (Pegasys)	0
3.6 Ropeginterferon Alfa-2b (Besremi)	0
3.7 Epoetin alfa (Eprex, Binocrit)	0
3.8 Epoetin beta (NeoRecormon, Mircera)	0
3.9 Epoetin zeta (Retacrit)	1
3.10 Darbepoetin (Aranesp)	0
3.11 No active treatment	2
3.12 Allogeneic stem cell transplant	0

Q4. How many patients were treated with **ruxolitinib (Jakavi)** in combination with **epoetin** in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

*Please include all types of epoetin – epoetin alfa, epoetin beta, epoetin zeta, darbepoetin alfa*

Name of medicine	Number patients treated
4.0 Ruxolitinib (Jakavi) + epoetin	2

**NON HODGKIN LYMPHOMA (NHL) AND CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)**

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
5.1 Acalabrutinib (Calquence)	18
5.2 Ibrutinib (Imbruvica)	17
5.3 Pirtobrutinib (Jaypirca)	0
5.4 Venetoclax (Venclyxto)	21
5.5 Zanubrutinib (Brukinsa)	5

Q6. How many patients with **Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma** – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
6.1 Acalabrutinib (Calquence)	5
6.2 Ibrutinib (Imbruvica)	1
6.3 Pirtobrutinib (Jaypirca)	0
6.4 Venetoclax (Venclyxto)	4
6.5 Zanubrutinib (Brukinsa)	0

Q7. How many patients with **Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma** were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
7.1 Ibrutinib + venetoclax	0
7.2 Obinutuzumab + venetoclax	0
7.3 Acalabrutinib monotherapy / maintenance	5
7.4 Zanubrutinib monotherapy / maintenance	0
7.5 Ibrutinib monotherapy / maintenance	4
7.6 Venetoclax monotherapy	0
7.7 Venetoclax + rituximab	5

**MANTLE CELL LYMPHOMA**

Q8. How many patients with **Mantle Cell Lymphoma** – ICD10 code = C831, C83.1 - were treated in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

	Number patients treated
8.0 Treated for Mantle Cell Lymphoma	0

Q8.1 How many patients with **Mantle Cell Lymphoma** were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
8.1 MaxiCHOP + rituximab + high dose Cytarabine or NORDIC protocol	0
8.2 Stem Cell Transplant	Unable to obtain this information
8.3 Rituximab + bendamustine + cytarabine	0
8.4 Rituximab + bendamustine	0
8.5 Ibrutinib	2
8.6 Rituximab + CHOP, Rituximab + CVP or rituximab + other chemo	9
8.7 Acalabrutinib + rituximab + bendamustine	0